Safety profile of statins;El perfil de seguridad de las estatinas

Revista Medica de Chile

Volumn 129, Issue 11, 2001, Pages 1237-1240

  Prieto D, Juan Carlos ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Adverse drug reaction reporting systems; Cerivastatin; Hidroxymethylglutaryl CoA reductase inhibitors; Rhabdomyolysis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

EDITORIAL; HUMAN;

ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0035523924     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. SACKS FM, PFEFFER MA, MOYE LA, ROULEAU JL, RUTHERFORD JD, COLE TG, ET AL, FOR THE CARE INVESTIGATORS. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
3. LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-57.
4. SHEPHERD J, COBBE SM, FORD I, ISLES CG, LORIMER AR, MACFARLANE PW, ET AL. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
5. DOWNS JR, CLEARFIELD M, WEIS S, WHITNEY E, SHAPIRO DR, BEERE PA, ET AL. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
6. UCAR M, MJORNDAL T, DAHLQVIST R. HMG-CoA Reductase Inhibitors and Myotoxicity. Drug Safety 2000; 22: 441-457.
7. DAVIDSON MH. Safety Profiles for the HMG-CoA Reductase Inhibitors. Drugs 2001; 61: 197-206.
8. MORITA I, SATO I, MA L, MUROTA S. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium. 1997; 5: 107-13.
9. GADBUT AP, CARUSO AP, GALPER JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995; 27: 2397-402.
10. Comunicación sobre riesgos de Medicamentos. Cerivastatina y casos de rabdomiolisis. Sistema Español de Farmacovigilancia. Julio 2001 ref: 2001/06.
11. Bayer Voluntarily Withdraws Baycol. FDA Talk Paper. August 8, 2001. www.fda.gov/bbs/topics /ANSWERS/2001/ANS01095.html
12. Cerivastatin and Rhabdomyolysis. Avoid Gemfibrozil. Australian Adverse Drug Reactions Bulletin Vol 20 (1), February 2001. www.health. gov.au/tga/docs/html/aadrbltn/aadrbidx.htm